Ashley Zehnder, an exotic animal veterinarian and cancer biologist, co-founded Fauna Bio in 2018, after recognizing the potential to translate insights from non-human mammalian biology into human therapeutics.
Podcast: How Fauna Bio Gleans Therapeutic Insights From Animals
In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.
More from Podcasts
• By
In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.
• By
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
• By
Harness Therapeutics' CEO talked to In Vivo about the company's strategy for expansion and partnering in the neurodegeneration space.
• By
Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.
More from Innovation
• By
Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
• By
Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.